Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RE...
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
About this item
Full title
Author / Creator
Passamonti, Francesco, Prof , Griesshammer, Martin, Prof , Palandri, Francesca, MD , Egyed, Miklos, Prof , Benevolo, Giulia, MD , Devos, Timothy, Prof , Callum, Jeannie, FRCPC , Vannucchi, Alessandro M, Prof , Sivgin, Serdar, MD , Bensasson, Caroline, PhD , Khan, Mahmudul, PhD , Mounedji, Nadjat, MD and Saydam, Guray, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydroxyurea. In this study, we assessed the eff...
Alternative Titles
Full title
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1859487768
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1859487768
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(16)30558-7
